Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Ahn, Inhye E., Underbayev, Chingiz, Albitar, Adam, Herman, Sarah E. M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Lymphoid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356450/
https://ncbi.nlm.nih.gov/pubmed/28049639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-719294
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items